525 related articles for article (PubMed ID: 27413114)
21. Ataxia telangiectasia syndrome: moonlighting ATM.
Zaki-Dizaji M; Akrami SM; Abolhassani H; Rezaei N; Aghamohammadi A
Expert Rev Clin Immunol; 2017 Dec; 13(12):1155-1172. PubMed ID: 29034753
[TBL] [Abstract][Full Text] [Related]
22. Functional classification of ATM variants in ataxia-telangiectasia patients.
Fiévet A; Bellanger D; Rieunier G; Dubois d'Enghien C; Sophie J; Calvas P; Carriere JP; Anheim M; Castrioto A; Flabeau O; Degos B; Ewenczyk C; Mahlaoui N; Touzot F; Suarez F; Hully M; Roubertie A; Aladjidi N; Tison F; Antoine-Poirel H; Dahan K; Doummar D; Nougues MC; Ioos C; Rougeot C; Masurel A; Bourjault C; Ginglinger E; Prieur F; Siri A; Bordigoni P; Nguyen K; Philippe N; Bellesme C; Demeocq F; Altuzarra C; Mathieu-Dramard M; Couderc F; Dörk T; Auger N; Parfait B; Abidallah K; Moncoutier V; Collet A; Stoppa-Lyonnet D; Stern MH
Hum Mutat; 2019 Oct; 40(10):1713-1730. PubMed ID: 31050087
[TBL] [Abstract][Full Text] [Related]
23. Recently emerging signaling landscape of ataxia-telangiectasia mutated (ATM) kinase.
Farooqi AA; Attar R; Arslan BA; Romero MA; ul Haq MF; Qadir MI
Asian Pac J Cancer Prev; 2014; 15(16):6485-8. PubMed ID: 25169474
[TBL] [Abstract][Full Text] [Related]
24. ATM mutations for surgeons.
Mansfield SA; Pilarski R; Agnese DM
Fam Cancer; 2017 Jul; 16(3):407-410. PubMed ID: 27988859
[TBL] [Abstract][Full Text] [Related]
25. Molecular basis of human ATM kinase inhibition.
Stakyte K; Rotheneder M; Lammens K; Bartho JD; Grädler U; Fuchß T; Pehl U; Alt A; van de Logt E; Hopfner KP
Nat Struct Mol Biol; 2021 Oct; 28(10):789-798. PubMed ID: 34556870
[TBL] [Abstract][Full Text] [Related]
26. DNA protein kinase-dependent G2 checkpoint revealed following knockdown of ataxia-telangiectasia mutated in human mammary epithelial cells.
Arlander SJ; Greene BT; Innes CL; Paules RS
Cancer Res; 2008 Jan; 68(1):89-97. PubMed ID: 18172300
[TBL] [Abstract][Full Text] [Related]
27. ATM mutation spectrum in Russian children with ataxia-telangiectasia.
Suspitsin E; Sokolenko A; Bizin I; Tumakova A; Guseva M; Sokolova N; Vakhlyarskaya S; Kondratenko I; Imyanitov E
Eur J Med Genet; 2020 Jan; 63(1):103630. PubMed ID: 30772474
[TBL] [Abstract][Full Text] [Related]
28. Ataxia-telangiectasia, ATM and genomic stability: maintaining a delicate balance. Two international workshops on ataxia-telangiectasia, related disorders and the ATM protein.
Shiloh Y
Biochim Biophys Acta; 1998 Oct; 1378(2):R11-8. PubMed ID: 9823376
[No Abstract] [Full Text] [Related]
29. ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.
Subhash VV; Tan SH; Yeo MS; Yan FL; Peethala PC; Liem N; Krishnan V; Yong WP
Mol Cancer Ther; 2016 Dec; 15(12):3087-3096. PubMed ID: 27638859
[TBL] [Abstract][Full Text] [Related]
30. Novel ATM mutations with ataxia-telangiectasia.
Liu XL; Wang T; Huang XJ; Zhou HY; Luan XH; Shen JY; Chen SD; Cao L
Neurosci Lett; 2016 Jan; 611():112-5. PubMed ID: 26628246
[TBL] [Abstract][Full Text] [Related]
31. Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs.
Kantidze OL; Velichko AK; Luzhin AV; Petrova NV; Razin SV
Trends Cancer; 2018 Nov; 4(11):755-768. PubMed ID: 30352678
[TBL] [Abstract][Full Text] [Related]
32. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
Menezes DL; Holt J; Tang Y; Feng J; Barsanti P; Pan Y; Ghoddusi M; Zhang W; Thomas G; Holash J; Lees E; Taricani L
Mol Cancer Res; 2015 Jan; 13(1):120-9. PubMed ID: 25232030
[TBL] [Abstract][Full Text] [Related]
33. Refractory T-cell/histiocyte-rich large B-cell lymphoma in a patient with ataxia-telangiectasia caused by novel compound heterozygous variants in ATM.
Sato D; Moriya K; Nakano T; Miyagawa C; Katayama S; Niizuma H; Sasahara Y; Kure S
Int J Hematol; 2021 Dec; 114(6):735-741. PubMed ID: 34424493
[TBL] [Abstract][Full Text] [Related]
34. Targeted disruption of Ataxia-telangiectasia mutated gene in miniature pigs by somatic cell nuclear transfer.
Kim YJ; Ahn KS; Kim M; Kim MJ; Park SM; Ryu J; Ahn JS; Heo SY; Kang JH; Choi YJ; Choi SJ; Shim H
Biochem Biophys Res Commun; 2014 Oct; 452(4):901-5. PubMed ID: 25193705
[TBL] [Abstract][Full Text] [Related]
35. Ataxia-telangiectasia: A review of clinical features and molecular pathology.
Amirifar P; Ranjouri MR; Yazdani R; Abolhassani H; Aghamohammadi A
Pediatr Allergy Immunol; 2019 May; 30(3):277-288. PubMed ID: 30685876
[TBL] [Abstract][Full Text] [Related]
36. Three new cases of ataxia-telangiectasia-like disorder: No impairment of the ATM pathway, but S-phase checkpoint defect.
Fiévet A; Bellanger D; Valence S; Mobuchon L; Afenjar A; Giuliano F; Dubois d'Enghien C; Parfait B; Pedespan JM; Auger N; Rieunier G; Collet A; Burglen L; Stoppa-Lyonnet D; Stern MH
Hum Mutat; 2019 Oct; 40(10):1690-1699. PubMed ID: 31033087
[TBL] [Abstract][Full Text] [Related]
37. DNA damage response and hematological malignancy.
Takagi M
Int J Hematol; 2017 Sep; 106(3):345-356. PubMed ID: 28374143
[TBL] [Abstract][Full Text] [Related]
38. Ataxia-telangiectasia gene (
Jerzak KJ; Mancuso T; Eisen A
Curr Oncol; 2018 Apr; 25(2):e176-e180. PubMed ID: 29719442
[TBL] [Abstract][Full Text] [Related]
39. ATM: the product of the gene mutated in ataxia-telangiectasia.
Lavin MF
Int J Biochem Cell Biol; 1999 Jul; 31(7):735-40. PubMed ID: 10467728
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy.
Vecchio D; Frosina G
Curr Drug Targets; 2016; 17(2):139-53. PubMed ID: 25382204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
